<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101256</url>
  </required_header>
  <id_info>
    <org_study_id>66/09</org_study_id>
    <nct_id>NCT01101256</nct_id>
  </id_info>
  <brief_title>Determination of Residual Anticoagulatory Effects of Fondaparinux</brief_title>
  <official_title>Determination of Residual Anticoagulatory Effects of Prophylactic or Therapeutic Treatment With Fondaparinux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine residual anticoagulatory effects of a prophylactic
      or therapeutic fondaparinux treatment i.e. prior to surgery/intervention, after pause of
      therapy etc.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>antiXa-levels (peak- and through-levels)</measure>
    <time_frame>between day 3 and day 14 after start of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>thromboembolic or bleeding episodes, HIT</measure>
    <time_frame>day 14 after start of therapy</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Anticoagulant Prophylaxis/Therapy</condition>
  <arm_group>
    <arm_group_label>Fondaparinux Prophylaxis group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Fondaparinux Therapy group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Citrated blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with s.c. anticoagulant therapy (fondaparinux)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fondaparinux therapy for at least 3 days

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Hemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Schindewolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J.W. Goethe University Hospital Frankfurt/M.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Schindewolf, MD</last_name>
    <phone>+49 (0)69 6301</phone>
    <phone_ext>5096</phone_ext>
    <email>marcschindewolf@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>J.W. Goethe University Hospital Frankfurt/M.</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Schindewolf, MD</last_name>
      <phone>+49 (0)69-6301</phone>
      <phone_ext>5096</phone_ext>
      <email>marcschindewolf@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Edelgard Lindhoff-Last, MD</last_name>
      <phone>+49 (0)69-6301</phone>
      <phone_ext>5096</phone_ext>
      <email>lindhoff-last@em.uni-frankfurt.de</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Schindewolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Paolucci F, Frasa H, Van Aarle F, Capdevla A, Clavies MC, van Dinther T, Donat F, Hendriks Y, van den Heuvel M, Nadal T, Lagrange F, Necciari J, Perez Y. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Clin Lab. 2003;49(9-10):451-60.</citation>
    <PMID>14572200</PMID>
  </reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>April 12, 2010</last_update_submitted>
  <last_update_submitted_qc>April 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Marc Schindewolf</name_title>
    <organization>Division of Vascular Medicine, Department of Internal Medicine, J.W.Goethe University Hospital Frankfurt/Main, Germany</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

